| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Inhaled insulin |
| Brand | Exubera® |
| Indication | Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. |
| Assessment Process | |
| Full pharmacoeconomic assessment commissioned by HSE | 01/04/2006 |
| NCPE assessment completed | 01/06/2006 |